Skip to main content
SpringerLink
Log in
Book cover

Handbook of Drug-Nutrient Interactions pp 617–662Cite as

Drug–Nutrient Interactions in the Elderly

  • Chapter
  • First Online:

  • 2970 Accesses

Part of the book series: Nutrition and Health ((NH))

Objectives

• Provide a description of who makes up the elderly population.

• Identify risk factors for drug–nutrient interactions in the elderly.

• Describe examples of drug–nutrient interactions in the elderly.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Salazar JA, Poon I, Nair M. Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkable. Expert Opin Drug Saf 2007;6:695–704.

    Article  Google Scholar 

  2. Administration on Aging, U.S. Department of Health and Humans Services. A profile of older Americans: 2007. Available at: http://www.aoa.gov/prof/statistics/profile/2007/2007profile.pdf. Accessed May 2008.

  3. Oskvig RM. Special problems in the elderly. Chest 1999;115(5):158–164.

    Article  Google Scholar 

  4. Basics of geriatric care: prevention of disease and disability. In: Beers MH, Berkow R, eds. The Merck Manual of Geriatrics, 3rd ed. Whitehouse Station: Merck Research Laboratories, 2000:46–53.

    Google Scholar 

  5. Rockwood K, Hogan DB, MacKnight C. Conceptualisation and measurement of frailty in elderly people. Drugs Aging 2000;17(4):295–302.

    Article  CAS  Google Scholar 

  6. Manton KG, Gu XL, Lamb VL. Change in chronic disability from 1982 to 2004/2005 as measured by long-term changes in function and health in the U.S. elderly population. Proc Natl Acad Sci 2006;103:18374–18379.

    Article  CAS  Google Scholar 

  7. Manton KG, Gu XL, Lowrimore GR. Cohort changes in active life expectancy in the U.S. elderly population: experience from the 1982–2004 national long-term care survey. J Gerontol 2008;63B:S269–S281.

    Google Scholar 

  8. Manton KG, Lamb VL, Gu XL. Medicare cost effect of recent U.S. disability trends in the elderly. J Aging Health 2007;19:359–381.

    Article  Google Scholar 

  9. Basics of geriatric care: biology of aging. In: Beers MH, Berkow R, eds. The Merck Manual of Geriatrics, 3rd ed. Whitehouse Station: Merck Research Laboratories, 2000:3–9.

    Google Scholar 

  10. Simonson W. Introduction to the aging process. In: Delafuente JC, Stewart RB, eds. Therapeutics in the Elderly, 3rd ed. Cincinnati: Harvey Whitney Books, 2001:1–39.

    Google Scholar 

  11. Devone CAJ. Comprehensive geriatric assessment: making the most of the aging years. Curr Opin Clin Nutr Metab Care 2002;5:19–24.

    Article  Google Scholar 

  12. Lassila HC, Stoehr GP, Ganguli M, et al. Use of prescription medications in an elderly rural population: the MoVIES project. Ann Pharmacother 1996;30:589–595.

    CAS  Google Scholar 

  13. Saini A, Birrer R, Harghel C, et al. Polypharmacy, complementary and alternative medicine in the elderly. P&T 2001;26(12):616–620, 627.

    Google Scholar 

  14. Delafeunte JC. Perspectives on geriatric pharmacotherapy. Pharmacotherapy 1991;11(3):222–224.

    Google Scholar 

  15. Baum C, Kennedy DL, Forbes MB, et al. Drug use in the United States in 1981. JAMA 1984;25:1293–1297.

    Article  Google Scholar 

  16. Coons JS, Johnson M, Chandler MHH. Sources of self-treatment information and use of home remedies and over-the-counter medications among older adults. J Geriatr Drug Ther 1992;7:71–82.

    Google Scholar 

  17. Chen LH, Liu S, Cook-Newell ME, Barnes K. Survey of drug use by the elderly and possible impact of drugs on nutritional status. Drug-Nutr Interact 1985;3:73–86.

    CAS  Google Scholar 

  18. Lewis CW, Frongillo EA, Roe DA. Drug-nutrient interactions in three long-term-care facilities. J Am Diet Assoc 1995;95:309–315.

    Article  CAS  Google Scholar 

  19. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002;287:337–344.

    Article  Google Scholar 

  20. Avorn J, Soumerai SB, Everitt DE, et al. A randomized trial of a program to reduce the use of psychoactive medications in a nursing home. N Engl J Med 1992;327:168–173.

    Article  CAS  Google Scholar 

  21. Tobias DE, Pulliam CC. General and psychotherapeutic medication use in 878 nursing homes: a 1997 national survey. Consult Pharm 1997;12:1401–1408.

    Google Scholar 

  22. Beers MH, Baran RW, Frenia K. Drugs and the elderly, part 1: the problems facing managed care. Am J Manag Care 2000;6:1313–1320.

    CAS  Google Scholar 

  23. Fanning KD, Ruby CM, Twersky JI, et al. The prevalence of dietary supplement and home remedy use by patients in a geriatric outpatient clinic. Consult Pharm 2002;17(11):972–978.

    Google Scholar 

  24. Dolder C, Lacro J, Dolder N, et al. Alternative medication use: results of a survey of older veterans. Consult Pharm 2002;17:653–662.

    Google Scholar 

  25. Ly J, Percy L, Dhanani S. Use of dietary supplements and their interactions with prescription drugs in the elderly. Am J Health-Syst Pharm 2002;59:1759–1762.

    CAS  Google Scholar 

  26. Marinac JS, Buchinger C, Godfrey L, et al. Vitamin and mineral supplement use among older Americans. Pharmacotherapy 2001;21:1268–1269.

    Google Scholar 

  27. Zeilmann CA, Dole EJ, Skipper B, et al. Herb use in Anglo and Hispanic elders. Pharmacotherapy 1999;19:1204.

    Google Scholar 

  28. Hanlon JT, Fillenbaum GG, Ruby CM, et al. Epidemiology of over-the-counter drug use in community dwelling elderly: United States perspective. Drugs Aging 2001;18(2):123–131.

    Article  CAS  Google Scholar 

  29. Anderson DL, Shane-McWhorter L, Crouch BI, et al. Prevalence and patterns of alternative medication use in a university hospital outpatient clinic serving rheumatology and geriatric patients. Pharmacotherapy 2000;20(8):958–966.

    Article  CAS  Google Scholar 

  30. Zeilmann CA, Dole EJ, Skipper BJ, et al. Use of herbal medicine by elderly Hispanic and non-hispanic white patients. Pharmacotherapy 2003;23(4):526–532.

    Article  Google Scholar 

  31. Anderson DL, Shane-McWhorter L, Crouch BI, et al. Prevalence and patterns of alternative medication use in a university hospital outpatient clinic serving rheumatology and geriatric patients. Pharmacotherapy 2000;20(8):958–966.

    Article  CAS  Google Scholar 

  32. Palisso G, Di Maro G, Galzerano D, et al. Pharmacological doses of vitamin E and insulin action in elderly subjects. Am J Clin Nutr 1994;59:1291–1296.

    Google Scholar 

  33. Corrigan JJ, Marcus FI. Coagulopathy associated with vitamin E ingestion. JAMA 1974;230:1300–1301.

    Article  Google Scholar 

  34. Graat JM, Schouten EG, Kok FJ. Effect of daily vitamin E and multivitamin-mineral supplementation on acute respiratory tract infections in elderly persons: a randomized controlled trial. JAMA 2002;288:715–721.

    Article  CAS  Google Scholar 

  35. Hanlon JT, Schmader KE, Boult C, et al. Use of inappropriate prescription drugs by older people. J Am Geriatr Soc 2002;50:26–34.

    Article  Google Scholar 

  36. Dhall J, Larrat P, Lapane KL. Use of potentially inappropriate drugs in nursing homes. Pharmacotherapy 2002;22(1):88–96.

    Article  Google Scholar 

  37. Hanlon JT, Fillenbaum GG, Schmader KE, et al. Inappropriate drug use among community-dwelling elderly. Pharmacotherapy 2000;20(5):575–582.

    Article  CAS  Google Scholar 

  38. Zhan C, Sangl J, Bierman AS, et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 medical expenditure panel survey. JAMA 2001;286:2823–2829.

    Article  CAS  Google Scholar 

  39. Schmader K, Hanlon JT, Weinberger M, et al. Appropriateness of medication prescribing in ambulatory elderly patients. J Am Geriatr Soc 1994;42:1241–1247.

    CAS  Google Scholar 

  40. Stuck AE, Beers MH, Steiner A, et al. Inappropriate medication use in community-residing older persons. Arch Intern Med 1994;154:2195–2200.

    Article  CAS  Google Scholar 

  41. Beers MH, Ouslander JG, Fingold SF, et al. Inappropriate medication prescribing in skilled-nursing facilities. Ann Intern Med 1992;117:684–689.

    CAS  Google Scholar 

  42. Strand LM, Morley PC, Cipolle RJ, et al. Drug-related problems: their structure and function. DICP 1990;24(11):1093–1097.

    CAS  Google Scholar 

  43. Hanlon JT, Shimp LA, Semla TP. Recent advances in geriatrics: drug-related problems in the elderly. Ann Pharmacother 2000;34:360–365.

    Article  CAS  Google Scholar 

  44. Hanlon JT, Schmader KE, Samsa GP, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol 1992;45(10):1045–1051.

    Article  CAS  Google Scholar 

  45. Samsa GP, Hanlon JT, Schmader KE, et al. A summated score for the medication appropriateness index: development and assessment of clinimetric properties including content validity. J Clin Epidemiol 1994;47(8):891–896.

    Article  CAS  Google Scholar 

  46. Hanlon JT, Gray SL, Schmader KE. Adverse drug reactions. In: Delafuente JC, Stewart RB, eds. Therapeutics in the Elderly, 3rd ed. Cincinnati: Harvey Whitney Books, 2001:289–314.

    Google Scholar 

  47. Nolan L, O’Malley K. Prescribing for the elderly Part1: sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc 1988;36:142–149.

    CAS  Google Scholar 

  48. Fields TS, Gurwitz JH, Avorn J, et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med 2001;161(3):1629–1634.

    Article  Google Scholar 

  49. Montamat SC, Cusack B. Overcoming problems with polypharmacy and drug misuse in the elderly. Clin Geriatr Med 1992;8(1):143–158.

    CAS  Google Scholar 

  50. Grymonpre RE, Mitenko PA, Sitar DS, et al. Drug-associated hospital admissions in older medical patients. J Am Geriatr Soc 1988;36:1092–1098.

    CAS  Google Scholar 

  51. Fouts M, Hanlon J, Pieper C, et al. Identification of elderly nursing facility residents at high risk for drug-related problems. Consult Pharm 1997;12:1103–1111.

    Google Scholar 

  52. Schneider JK, Mion LC, Frengley D. Adverse drug reactions in an elderly outpatient population. Am J Hosp Pharm 1992;49:90–96.

    CAS  Google Scholar 

  53. Thomas EJ, Brennan TA. Incidence and types of preventable adverse events in elderly patients: population based review of medical records. BMJ 2000;320:741–744.

    Article  CAS  Google Scholar 

  54. Beers MH. Aging as a risk factor for medication-related problems. Consult Pharm 1999;14(12):1337–1340.

    Google Scholar 

  55. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997;157(14):1531–1536.

    Article  CAS  Google Scholar 

  56. Hanlon JT, Shimp LA, Semla TP. Recent advances in geriatrics: drug-related problems in the elderly. Ann Pharmacother 2000;34:360–365.

    Article  CAS  Google Scholar 

  57. Willcox SM, Himmelstein DU, Woolhandler S. Inappropriate drug prescribing for the community-dwelling elderly. JAMA 1994;272:292–296.

    Article  CAS  Google Scholar 

  58. Zhan C, Sangl J, Bierman AS, et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the national 1996 medical expenditure panel survey. JAMA 2001;286:2823–2829.

    Article  CAS  Google Scholar 

  59. Pitkala KH, Strandberg TE, Tilvis RS. Inappropriate drug prescribing in home-dwelling, elderly patients: a population-based survey. Arch Intern Med 2002;162:1707–1712.

    Article  Google Scholar 

  60. Aparasu RR, Sitzman SJ. Inappropriate prescribing for elderly outpatients. Am J Health Syst Pharm 1999;56:433–439.

    CAS  Google Scholar 

  61. Hanlon JT, Schmader KE, Koronkowski MJ, et al. Adverse drug events in high risk older outpatients. J Am Geriatr Soc 1997;45:945–948.

    CAS  Google Scholar 

  62. Chrischilles EA, Segar ET, Wallace RB. Self-reported adverse drug reactions and related resource use. Ann Intern Med 1992;117:634–640.

    CAS  Google Scholar 

  63. Cooper JW. Probable adverse drug reactions in a rural geriatric nursing home population: a four-year study. J Am Geriatr Soc 1996;44:194–197.

    CAS  Google Scholar 

  64. Gerety MB, Cornell JE, Plichta DT, et al. Adverse events related to drugs and drug withdrawal in nursing home residents. J Am Geriatr Soc 1993;41:1326–1332.

    CAS  Google Scholar 

  65. Bates DW, Leape LL, Petrycki S, et al. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med 1993;8:289–294.

    Article  CAS  Google Scholar 

  66. Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse dug events in nursing homes. Am J Med 2000;109:87–94.

    Article  CAS  Google Scholar 

  67. Gurwitz JH, Rochon P. Improving the quality of medication use in elderly patients: a not-so-simple prescription. Arch Intern Med 2002;162:1670–1672.

    Article  Google Scholar 

  68. Bootman JL, Harrison DL, Cox E. The health care cost of drug-related morbidity and mortality in nursing facilities. Arch Intern Med 1997;157:2089–2096.

    Article  CAS  Google Scholar 

  69. Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost-of- illness model. Arch Intern Med 1995;155:1949–1956.

    Article  CAS  Google Scholar 

  70. Anonymous. Guidelines abstracted from consensus recommendations for the management of chronic heart failure. J Am Geriatr Soc.2000;48:1521–1524.

    Google Scholar 

  71. Anonymous. The use of oral anticoagulants in older people. J Am Geriatr Soc 2000;48:224–227.

    Google Scholar 

  72. Mendelson G, Ness J, Aranow WS. Drug treatment of hypertension in older persons in an academic hospital-based geriatrics practice. J Am Geriatr Soc 1999;47:597–599.

    CAS  Google Scholar 

  73. Gattis WA, Larsen RL, Hasselblad V. Is optimal angiotensin-converting enzyme inhibitor dosing neglected in elderly patients with heart failure. Am Heart J 1998;136:43–48.

    Article  CAS  Google Scholar 

  74. Luzier AB, DiTusa L. Underutilization of ACE inhibitors in heart failure. Pharmacotherapy 1999;19(11):1296–1307.

    Article  CAS  Google Scholar 

  75. Pahor M, Shorr JI, Somes GW, et al. Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic hypertension in the elderly program. Arch Intern Med 1998;158:1340–1345.

    Article  CAS  Google Scholar 

  76. Smith NL, Psaty BM, Pitt B, et al. Temporal patterns in the medical treatment of congestive heart failure with angiotensin-converting enzyme inhibitors in older adults, 1989 through 1995. Arch Intern Med 1998;158:1074–1080.

    Article  CAS  Google Scholar 

  77. Krumholz HA, Radford MJ, Wang Y, et al. Early beta-blocker therapy for acute myocardial infarction in elderly patients. Ann Intern Med 1999;131:648–654.

    CAS  Google Scholar 

  78. Krumholz HM, Radford MJ, Wang Y, et al. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction. JAMA 1998;280(7):623–629.

    Article  CAS  Google Scholar 

  79. Williams ME. Clinical implications of aging physiology. Am J Med 1984;76:1048–1054.

    Article  Google Scholar 

  80. Kenney RA. Physiology of Aging. Clin Geriatr Med 1985;1(1):37–59.

    CAS  Google Scholar 

  81. Swift CG. Pharmacodynamics: changes in homeostatic mechanisms, receptor and target organ sensitivity in the elderly. Br Med Bull 1990;46(1):36–52.

    CAS  Google Scholar 

  82. Hanratty CG, McGlinchey P, Johnston DG, et al. Differential pharmacokinetics of digoxin in elderly patients. Drugs Aging 2000;17(5):353–362.

    Article  CAS  Google Scholar 

  83. Sproule B, Hardy BG, Shulman KI. Differential pharmacokinetics of lithium in elderly patients. Drugs Aging 2000;16(3):165–177.

    Article  CAS  Google Scholar 

  84. Montamat SC, Cusack BJ, Vestal RE. Management of drug therapy in the elderly. N Engl J Med 1989;321(5) 303–321.

    Article  CAS  Google Scholar 

  85. Berkey DB, Shay K. General dental care for the elderly. Clin Geriatr Med 1992;8(3):579–597.

    CAS  Google Scholar 

  86. Altman DF. Changes in gastrointestinal, pancreatic, biliary, and hepatic function with aging. Gastroenterol Clin North Am 1990;19(2):227–234.

    CAS  Google Scholar 

  87. Hurwitz A, Brady DA, Schaal SE, et al. Gastric acidity in older adults. JAMA 1997;278(8):659–662.

    Article  CAS  Google Scholar 

  88. Welling P. Nutrient effects on drug metabolism and action in the elderly. Drug-Nutr Interact 1985;4:173–207.

    CAS  Google Scholar 

  89. Ensrud KE, Duong T, Cauley JA, et al. Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Ann Intern Med 2000;132:345–353.

    CAS  Google Scholar 

  90. Charles P. Calcium absorption and calcium bioavailability. J Intern Med 1992;231:161–168.

    Article  CAS  Google Scholar 

  91. Chiu KM. Efficacy of calcium supplements on bone mass in postmenopausal women. J Gerontol: Med Sci 1998;54A96:M275–280.

    Google Scholar 

  92. Pattanaungkul S, Riggs BL, Yergey Al, et al. Relationship of intestinal calcium absorption to 1,25-dihydroxyvitamin D [1,23(OH)2D] levels in young versus elderly women: evidence for age-related intestinal resistance to 1,25(OH)2D action. J Clin Endocrinol Metab 2000;85(11):4023–4027.

    Article  CAS  Google Scholar 

  93. Holdsworth MT, Forman WB, Killilea TA, et al. Transdermal fentanyl disposition in elderly subjects. Gerontology 1994;40:32–37.

    Article  CAS  Google Scholar 

  94. Crome P, Flanagan RJ. Pharmacokinetic studies in elderly people: are they necessary? Clin Pharmacokinet 1994;26(4):243–247.

    Article  CAS  Google Scholar 

  95. Chapron DJ. Drug disposition and response. In: Delafuente JC, Stewart RB, eds. Therapeutics in the Elderly, 3rd ed. Cincinnati: Harvey Whitney Books, 2001:257–288.

    Google Scholar 

  96. Hanlon JT, Ruby CM, Guay D, et al. Geriatrics In: DiPiro JT, Talbert RL, Yee GC, et al., eds. Pharmacotherapy: A Pathophysiologic Approach, 5rd ed. New York: McGraw-Hill, 2002:79–89.

    Google Scholar 

  97. Danziger RS, Tobin JD, Becker LC, et al. The age-associated decline in glomerular filtration in healthy normotensive volunteers: lack of relationship to cardiovascular performance. J Am Geriatr Soc 1990;38:1127–1132.

    CAS  Google Scholar 

  98. Meyer BR. Renal function in aging. J Am Geriatr Soc 1989;37:791–800.

    CAS  Google Scholar 

  99. Rowe JW, Andres RA, Robin FD, et al. Age adjusted normal standards for creatinine in man. Ann Intern Med 1976;84:567–569.

    CAS  Google Scholar 

  100. Beck LH. The aging kidney: defending a delicate balance of fluid and electrolytes. Geriatrics 2000;55(4):26–28, 31–32.

    CAS  Google Scholar 

  101. Bennett WM. Guide to drug dosage in renal failure. Clin Pharmacokinet 1988;15:326–354.

    Article  CAS  Google Scholar 

  102. Lam YWF, Banerji S, Hatfield C, et al. Principles of drug administration in renal insufficiency. Clin Pharmacokinet 1997;32(1):30–57.

    Article  CAS  Google Scholar 

  103. Appel HM. Coping with renal insufficiency in the elderly. Consult Pharm 2000;15(2):127–133.

    Google Scholar 

  104. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16(1):31–41.

    Article  Google Scholar 

  105. U.S. Food and Drug Administration. Guidance for industry: content and format for geriatric labeling, October 2001. Available from: http://www.fda.gov/cber/guidelines.htm. Accessed May 2008.

  106. Hutt PB, Merrill RA, Grossman LA, eds. Food and drug law: cases and materials, 3rd ed. New York: Foundation Press, 2007.

    Google Scholar 

  107. Abernethy DR. Altered pharmacodynamics of cardiovascular drugs and their relation to altered pharmacokinetics in elderly patients. Clin Geriatr Med 1990;6(2):285–292.

    CAS  Google Scholar 

  108. Hammerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly. Clin Pharmacokinet 1998;35(1):49–64.

    Article  CAS  Google Scholar 

  109. Reidenberg MM, Kevy M, Warner H, et al. Relationship between diazepam dose, plasma level, age, and central nervous system depression. Clin Pharmacol Ther 1978;23:371–374.

    CAS  Google Scholar 

  110. Greenblatt DL, Divoll M, Harmatz JS, et al. Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. Clin Pharmacol Ther 1981;30:475–486.

    Article  CAS  Google Scholar 

  111. Gurwitz JH, Avorn J, Ross-Degnan D, et al. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 1992;116:901–904.

    CAS  Google Scholar 

  112. Heinsimer JA, Lefkowitz RJ. The impact of aging on adrenergic receptor function: clinical and biochemical aspects. J Am Geriatr Soc 1985;33(3):184–188.

    CAS  Google Scholar 

  113. U.S. Food and Drug Administration. Guideline for industry: studies in support of special populations: geriatrics, August 1994. Available from: http://www.fda.gov/cder/guidance/iche7.pdf. Accessed May 2008.

  114. Morley JE. Anorexia of aging: physiologic and pathologic. Am J Clin Nutr 1997;66:760–773.

    CAS  Google Scholar 

  115. Corti MC, Guralnik JM, Salive ME, Sorkin JD. Serum albumin level and physical disability as predictors of mortality in older persons. JAMA 1994;272:1036–1042.

    Article  CAS  Google Scholar 

  116. Nutrition Screening Initiative. Nutrition interventions manual for professionals caring for older Americans. Washington, DC: Nutrition Screening Initiative, 1992.

    Google Scholar 

  117. Vellas B, Garry PJ, Guigoz Y, eds. Mini Nutritional Assessment (MNA): research and practice in the elderly. Nestlé Nutrition Workshop Series, Clinical & Performance Programme, volume 1. Basel, Switzerland:S. Karger AG, 1999.

    Google Scholar 

  118. Vellas B, Lauque S, Andrieu S, et al. Nutrition assessment in the elderly. Curr Opin Clin Nutr Metab Care 2001;4:5–8.

    Article  CAS  Google Scholar 

  119. Omran ML, Morley JE. Assessment of protein energy malnutrition in older persons, part I: history, examination, body composition and screening tools. Nutrition 2000;16:50–63.

    Article  CAS  Google Scholar 

  120. Morley JE, Silver AJ. Nutritional issues in nursing home care. Ann Intern Med 1995;123:850–859.

    CAS  Google Scholar 

  121. High KP. Nutritional strategies to boost immunity and prevent infection in elderly individuals. Clin Infect Dis 2001;33:1892–1900.

    Article  CAS  Google Scholar 

  122. Aghdassi E, McArthur M, Liu B, et al. A comparison of the diet in a population of institutionalized Canadian elderly to the dietary reference intake. Am J Clin Nutr 2002;75(suppl):339–340S.

    Google Scholar 

  123. Riquelme R, Torres A, El-Ebiary M, et al. Community-acquired pneumonia in the elderly: clinical and nutritional aspects. Am J Respir Crit Care Med 1997;156:1908–1914.

    CAS  Google Scholar 

  124. Cederholm T, Järgén C, Hellström K. Outcome of protein-energy malnutrition in elderly medical patients. Am J Med 1995;98:67–74.

    Article  CAS  Google Scholar 

  125. Morley JE. Anorexia, body composition, and ageing. Curr Opin Clin Nutr Metab Care 2001;4:9–13.

    Article  CAS  Google Scholar 

  126. Sharkey JR, Branch LG, Zohoori N, et al. Inadequate nutrient intakes among homebound elderly and their correlation with individual characteristics and health-related factors. Am J Clin Nutr 2002;76:1435–1445.

    CAS  Google Scholar 

  127. Janssen HCJP, Samson MM, Verhaar HJJ. Vitamin D deficiency, muscle function, and falls in elderly people. Am J Clin Nutr 2002;75:611–615.

    CAS  Google Scholar 

  128. Bianchetti A, Rozzini R, Carabellese C, et al. Nutritional intake, socioeconomic conditions, and health status in a large elderly population. J Am Geriatr Soc 1990;38:521–526.

    CAS  Google Scholar 

  129. Campion EW. Home alone, and in danger. N Engl J Med 1996;334:1738–1739.

    Article  CAS  Google Scholar 

  130. Duthie SJ, Whalley LJ, Collins AR, et al. Homocysteine, B vitamin status, and cognitive function in the elderly. Am J Clin Nutr 2002;75:908–913.

    CAS  Google Scholar 

  131. Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 1988;318:1720–1728.

    Article  CAS  Google Scholar 

  132. Baik HW, Russell RM. Vitamin B12 deficiency in the elderly. Annu Rev Nutr 1999;19:357–377.

    Article  CAS  Google Scholar 

  133. Russell RM, Suter PM. Vitamin requirements of elderly people: an update. Am J Clin Nutr 1993;58:4–14.

    CAS  Google Scholar 

  134. Institute of Medicine. Dietary reference intakes: the essential guide to nutrient requirements. Washington, DC: National Academy Press, 2006.

    Google Scholar 

  135. Bates CJ, Walmsley CM, Prentice A, Finch S. Use of medicines by older people in a large British national survey, and their relation to vitamin status indices. Publ Health Nutr 1999;2:15–22.

    CAS  Google Scholar 

  136. Drinka PJ, Goodwin JS. Prevalence and consequences of vitamin deficiency in the nursing home: a critical review. J Am Geriatr Soc 1991;39:1008–1017.

    CAS  Google Scholar 

  137. Pennypacker LC, Allen RH, Kelly JP, et al. High prevalence of cobalamin deficiency in elderly outpatients. J Am Geriatr Soc 1992;40:1197–1204.

    CAS  Google Scholar 

  138. Lindenbaum J, Rosenberg I, Wilson P, et al. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr 1994;60:2–11.

    CAS  Google Scholar 

  139. Kant AK, Moser-veillon PB, Reynolds RD. Effect of age on changes in plasma erythrocyte and urinary B-6 vitamers after an oral vitamin B-6 load. Am J Clin Nutr 1988;48:1284–1290.

    CAS  Google Scholar 

  140. Ferroli CE, Trumbo PR. Bioavailability of vitamin B-6 in young and older men. Am J Clin Nutr 1994;60:68–71.

    CAS  Google Scholar 

  141. Guilland JC, Bereski-Reguig B, Lequeu B, et al. Evaluation of pyridoxine intake and pyridoxine status among aged institutionalized people. Int J Vit Nutr Res 1984;54:185–193.

    CAS  Google Scholar 

  142. Pannemans DLE, Van den Berg H, Westerterp KR. The influence of protein intake on vitamin B-6 metabolism differs in young and elderly humans. J Nutr 1994;124:1207–1214.

    CAS  Google Scholar 

  143. Sacks GS. Nutritional considerations. In: Delafuente JC, Stewart RB, eds. Therapeutics in the elderly, 3rd ed. Cincinnati, OH: Harvey Whitney Books Co., 2001:599–626.

    Google Scholar 

  144. Hartz SC. Proceedings: International conference on nutrients, medicines and aging. Drug-Nutr Interact 1985;4:3–263

    Google Scholar 

  145. Malone M. Nutrition and the elderly. Pharmacy Times 1997;55–63.

    Google Scholar 

  146. Miller CA. Drug/Food/Food supplements interactions. Geriatric Nurs 1999;20(3):164,168.

    Article  CAS  Google Scholar 

  147. Schmidt LE, Dalhoff K. Food-drug interactions. Drugs 2002;62(10):1481–1502.

    Article  CAS  Google Scholar 

  148. Lisi DM. Potential food-drug interactions in a VA nursing home population [abstract]. J Am Geriatr Soc 1999;47(9):S98.

    Google Scholar 

  149. Gauthier I, Malone M, Lesar TS, et al. Comparison of programs for preventing drug-nutrient interactions in hospitalized patients. Am J Health Syst Pharm 1997;54(4):405–411.

    CAS  Google Scholar 

  150. Maka D, Murphy LK. Drug-nutrient interactions: a review. AACN 2000;11(4):580–589.

    Article  CAS  Google Scholar 

  151. Boyd JA, Hospodka RJ, Bustamante P, et al. Nutritional considerations in the elderly. Am Pharm 1991;NS31(4):45–50.

    CAS  Google Scholar 

  152. Chan LN. Drug-nutrient interaction in clinical nutrition. Curr Opin Clin Nutr Metab Care 2002;5(3):327–332.

    Article  Google Scholar 

  153. Roe DA. Drug and nutrient interactions in the elderly diabetic. Drug-Nutr Interact 1988;5:195–203.

    CAS  Google Scholar 

  154. Roe DA. Drug and nutrient interactions in elderly cardiac patients. Drug-Nutr Interact 1988;5:205–212.

    CAS  Google Scholar 

  155. Fortes C, Forastiere F, Agabiti N, et al. The effect of zinc and vitamin A supplementation on immune response in an older population. J Am Geriatr Soc 1998;46:19–26.

    CAS  Google Scholar 

  156. Graat JM, Schouten EG, Kok FJ. Effect of daily vitamin E and multivitamin-mineral supplementation on acute respiratory tract infections in elderly persons: a randomized controlled trial. JAMA 2002;288:715–721.

    Article  CAS  Google Scholar 

  157. Gold JL, Laxer D, Dergal JM, et al. Herbal-drug therapy interactions: a focus on dementia. Curr Opin Clin Nutr Metab Care 2001;4:29–34.

    Article  CAS  Google Scholar 

  158. Carillo JA, Benitez J. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet 2000;39(2):127–153.

    Article  Google Scholar 

  159. Miller CA. Caffeine, nicotine, and drugs. Geriatr Nurs 1996;17(1):46–47.

    Article  CAS  Google Scholar 

  160. Barrick C, Connors GJ. Relapse prevention and maintaining abstinence in older adults with alcohol-use disorders. Drugs Aging 2002;19(8):583–594.

    Article  Google Scholar 

  161. LCB-226.Alcohol Abuse and Older People: A Hidden Problem. Pennsylvania Liquor Control Board, 1998. Available from: http://www.lcb.state.pa.us/edu/

  162. Rink A, Hays RD, Moore AA, et al. Alcohol-related problems in older persons: determinates, consequences and screening. Arch Intern Med 1996;156(11):1150–1156.

    Article  Google Scholar 

  163. Ewing HA. Detecting alcoholism. The CAGE questionnaire. JAMA 1984;252(14):1905–1907.

    Article  CAS  Google Scholar 

  164. Adams WL, Barry KL, Fleming MF. Screening for problem drinking in older primary care patients. JAMA 1996;276(24):1964–1967.

    Article  CAS  Google Scholar 

  165. Moore AA, Seeman T, Morgenstern H, et al. Are there differences between older persons who screen positive on the CAGE questionnaire and the Short Michigan Alcoholism Screening Test-Geriatric version? J Am Geriatr Soc 2002;50(5):858–862.

    Article  Google Scholar 

  166. Reid MC, Concato J, Rowle VR, et al. Alcohol use and functional disability among cognitively impaired adults. J Am Geriatr Soc 1999;47:854–859.

    CAS  Google Scholar 

  167. Kane GC, Lipsky JJ. Drug–rapefruit juice interactions. Mayo Clin Proc 2000;75(9):933–942.

    Article  CAS  Google Scholar 

  168. Lilley LL, Guanci R. Grapefruit and medication. Am J Nurs 1998;98(12):10.

    Article  Google Scholar 

  169. Rodvold KA, Meyer J. Drug–food interactions with grapefruit juice. Infect Med 1996;13(10):868, 871–873, 912.

    Google Scholar 

  170. Spence DJ. Drug interactions with grapefruit: whose responsibility is it to warn the public? Clin Pharmacol Ther 1997;61(4):395–400.

    Article  CAS  Google Scholar 

  171. Dresser GK, Bailey DG, Carruthers SG. Grapefruit juice-felodipine interaction in the elderly. Clin Pharmacol Ther 2000;68:28–34.

    Article  CAS  Google Scholar 

  172. Byeth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin: a randomized controlled trial. Ann Intern Med 2000;133(9):687–695.

    Google Scholar 

  173. O’Connell MB, Kowal PR, Allivato CJ, et al. Evaluation of warfarin initiation regimens in elderly inpatients. Pharmacotherapy 2000;20(8):923–930.

    Article  Google Scholar 

  174. Gurwitz MJ, Rochon PA, Avorn J. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. J Am Geriatr Soc 1997;45(9):1060–1065.

    Google Scholar 

  175. Wells PS, Holbrook AM, Crowther NR, et al. Interactions of warfarin with drugs and food. Ann Intern Med 1994;121(9):676–683.

    CAS  Google Scholar 

  176. Blickstein D, Shalkai M, Inbal A. Warfarin antagonism by avocado. Lancet 1991;337:915.

    Article  Google Scholar 

  177. Dickerson RN, Garmon WM, Kuhl DA, Minard G, Brown RO. Vitamin K-independent warfarin resistance after concurrent administration of warfarin and continuous enteral nutrition. Pharmacotherapy 2008;28:308–313.

    Article  CAS  Google Scholar 

  178. Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. Am J Health-Syst Pharm 1999;56:125–138.

    CAS  Google Scholar 

  179. Cupp MJ. Herbal remedies: adverse effects and drug interactions. Am Fam Physician 1999;59(5):1239–1244.

    CAS  Google Scholar 

  180. Winter ME. Phenytoin. In: Koda-Kimble MA, Young LY, eds. Basic Clinical Pharmacokinetics, 3rd ed. Vancouver: Applied Therapeutics Inc, 1994:313–348.

    Google Scholar 

  181. Wilder BJ, Leppik I, Hietpas TJ, et al. Effect of food on absorption of Dilantin Kapseals and Mylan extended phenytoin sodium capsules. Neurology 2001;57(4):582–589.

    CAS  Google Scholar 

  182. Cook J, Randinitis E, Wilder BJ. Effect of food on the bioavailability of 100 mg Dilantin Kapseals. Neurology 2001;57(4):698–700.

    CAS  Google Scholar 

  183. Jacobson AF. Minimizing phenytoin and tube-feeding interactions. Am J Nurs 1998;98(6):16.

    Google Scholar 

  184. Marvel ME, Bertino JS. Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension. J Parenter Enteral Nutr 1991;15(3):316–318.

    Article  CAS  Google Scholar 

  185. Doak KK, Haas CE, Dunnigan KJ, et al. Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings. Pharmacotherapy 1998;18(3):637–645.

    CAS  Google Scholar 

  186. Rodman DP, Stevenson TL, Ray TR. Phenytoin malabsorption after jejunostomy tube delivery. Pharmacotherapy 1995;15(6):801–805.

    CAS  Google Scholar 

  187. Lewis DP, VanDyke DC, Willhite LA, et al. Phenytoin-folic acid interactions. Ann Pharmacother 1995;29(7–8):726–735.

    CAS  Google Scholar 

  188. Maxwell JD, Hunter J, Stewart DA, et al. Folate deficiency after anticonvulsant drugs: an effect of hepatic enzyme induction? BMJ 1972;1(795):297–299.

    Article  CAS  Google Scholar 

  189. Spray GH, Burns DG. Folate deficiency and anticonvulsant drugs. BMJ 1972;2(806):167–168.

    Article  CAS  Google Scholar 

  190. Andreasen PB, Hansen JM, Skovsted L, et al. Folic acid and phenytoin metabolism. Lancet 1971;1(7700):645.

    Article  CAS  Google Scholar 

  191. Baylis EM, Crowley JM, Preece JM, et al. Influence of folic acid on blood-phenytoin levels. Lancet 1971;1(7689):62–64.

    Article  CAS  Google Scholar 

  192. Blain H, Hamdan KA, Blain A, et al. Aplastic anemia induced by phenytoin: a geriatric case with severe folic acid deficiency. J Am Geriatr Soc 2002;50(2):396–397.

    Article  Google Scholar 

  193. Spina E, Scordo MG. Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 2002;19(4):299–320.

    Article  CAS  Google Scholar 

  194. Cramer C. Hypertensive crisis from drug–food interaction. Am J Nurs 1997;97(5):32.

    Article  CAS  Google Scholar 

  195. Volz HP, Gleiter CH. Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging 1998;13(5):341–355.

    Article  CAS  Google Scholar 

  196. White R, Ashworth A. How drug therapy can affect, threaten, and compromise nutritional status. J Hum Nutr Diet 2000;13(2):119–129.

    Article  Google Scholar 

  197. Mueller BA, Brierton DG, Abel SR, et al. Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 1994;38(9):2101–2105.

    CAS  Google Scholar 

  198. Tomkin GH, Hadden DR, Weaver JA, et al. Vitamin-B12 status of patients on long-term metformin therapy. BMJ 1971;2:685–687.

    Article  CAS  Google Scholar 

  199. Andres E, Noel E, Goichot B. Metformin-associated vitamin B12deficiency. Arch Intern Med 2002;162(19):2251–2252.

    Article  Google Scholar 

  200. Gilligan MA. Metformin and vitamin B12 deficiency. Arch Intern Med 2002;162(4):484–485.

    Article  Google Scholar 

  201. Bauman WA, Shaw S, Jayatilleke E, Spungen AM, Herbert V. Increased intake of calcium revises vitamin B12 malabsorption induced by metformin. Diabetes Care 2000;23(9):1227–1231.

    Article  CAS  Google Scholar 

  202. Eikelboom JW, Lonn E, Genest J, et al. Homocysteine and cardiovascular disease: a critical review of the epidemiology evidence. Ann Intern Med 1999;131:363–375.

    CAS  Google Scholar 

  203. Bostom AG, Rosenberg IH, Silbershatz H, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham study. Ann Intern Med 1999;131:352–355.

    CAS  Google Scholar 

  204. Campbell NRC, Hasinoff BB, Stalts H, et al. Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. Ann Intern Med 1992;117:1010–1013.

    CAS  Google Scholar 

  205. Sperber AD, Liel Y. Evidence for interference with the intestinal absorption of levothyroxine by aluminum hydroxide. Arch Intern Med 1992;152:183–184.

    Article  CAS  Google Scholar 

  206. Liel Y, Sperber AD, Shany S. Nonspecific intestinal adsorption of levothyroxine by aluminum hydroxide. Am J Med 1994;97:363–365.

    Article  CAS  Google Scholar 

  207. Liel Y, Harman-Boehm I, Shany S. Evidence for a clinically important adverse effect of fiber-enriched diet on the bioavailability of levothyroxine in adult hypothyroid patients. J Clin Endocrinol Metab 1996;81:857–859.

    Article  CAS  Google Scholar 

  208. Singh M, Singh PN, Herschman JM. Effect of calcium carbonate on the absorption of levothyroxine. JAMA 2000;283(21):2822–2825.

    Article  CAS  Google Scholar 

  209. Mersebach H, Rasmussen AK, Kirkegaard L, et al. Intestinal adsorption of levothyroxine by antacids and laxatives: case stories and in vitro experiments. Pharmacol Toxicol 1999;84(3):107–109.

    Article  CAS  Google Scholar 

  210. Fosamax (alendronate sodium) prescribing information. Merck and Co, Inc. Whitehouse Station, NJ. February 2008. http://www.fda.gov/cder/foi/label/2008/020560s052,021575s013,021762s006lbl.pdf. Accessed May 2008.

  211. Actonel (risedronate sodium) prescribing information. Sanofi-Aventis Pharmaceuticals, Inc. Bridgewater, NJ. July 2007. http://www.fda.gov/cder/foi/label/2007/020835s028lbl.pdf. Accessed May 2008.

  212. Denman SJ. Esophagitis associated with the use of alendronate. J Am Geriatr Soc 1997;45(5):662.

    Google Scholar 

  213. Cummings SR, Black DM, Thompson DE, et al. Affect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 1998;280(24):2077–2082.

    Article  CAS  Google Scholar 

  214. Ravn P, Bidstrup M, Wasnich RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study: a randomized, controlled trial. Ann Intern Med 1999;131:935–942.

    CAS  Google Scholar 

  215. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized, controlled trial. JAMA 1999;282(14):1344–1352.

    Article  CAS  Google Scholar 

  216. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333–340.

    Article  CAS  Google Scholar 

  217. Thjodleifsson B. Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors. Drugs Aging 2002;19(12):911–927.

    Article  CAS  Google Scholar 

  218. Lazzaroni M, Bianchi PG. Treatment of peptic ulcer in the elderly. Proton pump inhibitors and histamine H2 receptor antagonists. Drugs Aging 1996;9(4):251–261.

    Article  CAS  Google Scholar 

  219. Ruscin JM, Page RL, Valuck RJ. Vitamin B(12) deficiency associated with histamine (2)- receptor antagonists and a proton pump inhibitor. Ann Pharmacother 2002;36(5):812–816.

    Article  Google Scholar 

  220. Andres E, Kaltenbach G, Perrin AE, et al. Food–cobalamin malabsorption in the elderly. Am J Med 2002;113(4):351–352.

    Article  Google Scholar 

  221. Force RW, Meeker AD, Cady PS, et al. Increased vitamin B12 requirement associated with chronic acid suppression therapy. Ann Pharmacother 2003;37:490–493.

    Google Scholar 

  222. Steinmetz KL. Colesevelam hydrochloride. Am J Health-Syst Pharm 2002;59(10):932–939.

    CAS  Google Scholar 

  223. Schiller LR. The therapy of constipation. Aliment Pharmacol Ther 2001;15(6):749–763.

    Article  CAS  Google Scholar 

  224. Eriksson T, Granerus AK, Linde A, et al. ‘On-off’ phenomenon in Parkinson’s disease: relationship between dopa and other large neutral amino acids in plasma. Neurology 1988;38(8):1245–1248.

    CAS  Google Scholar 

  225. Nutt JG, Woodward WR, Hammerstad JP, et al. Relation to levodopa absorption and transport. N Engl J Med 1984;310(8):483–488.

    Article  CAS  Google Scholar 

  226. Cooper MK, Brock DG, McDaniel CM. Interaction between levodopa and enteral nutrition. Ann Pharmacother 2008;42:439–442.

    Article  CAS  Google Scholar 

  227. Olanow CW, Watts RL, Koller WC. An algorithm for the management of Parkinson’s disease: treatment guidelines. Neurology 2001;56(11):S1–88.

    CAS  Google Scholar 

  228. Maixner SM, Mellow Am, Tandon R. The efficacy, safety and tolerability of antipsychotics in the elderly. J Clin Psychiatry 1999;60:S29–41.

    Article  Google Scholar 

  229. Wallace JI, Shwartz RS, LaCriox A, et al. Involuntary weight loss in older outpatients: incidence and clinical significance. J Am Geriatr Soc 1995;43:329–337.

    CAS  Google Scholar 

  230. Marton KI, Soc HC, Krupp JR, et al. Involuntary weight loss: diagnostic and prognostic significance. Ann Intern Med 1981;95:568–574.

    CAS  Google Scholar 

  231. Pytlarz A. Medications and involuntary weight loss: looking beyond the obvious. Consult Pharm 2002;17(6):485–486, 488, 491–492, 494–495.

    Google Scholar 

  232. Department of Health and Human Services, Centers for Medicare & Medicaid Services. Available from: http://www.cms.hhs.gov/SurveyCertificationGenInfo/downloads/SCLetter08-28.pdf. Accessed, 2008.

  233. Miller LJ, Kwan RC. Pharmacological treatment of undernutrition in the geriatric patient. Consult Pharm 2002;17:739–747.

    Google Scholar 

  234. Worrel JA, Marken PA, Beckman SE, et al. Atypical antipsychotic agents: a critical review. Am J Health-Syst Pharm 2000;57:238–258.

    CAS  Google Scholar 

  235. Wick JY. Drug-induced weight changes in residents of long-term care facilities. Consult Pharm 1998;13(12):1337–1340, 1343–1344, 1347–1348.

    Google Scholar 

  236. Carnahan RM, Lund BC, Perry PJ. Ziprasidone, a new atypical antipsychotic drug. Pharmacotherapy 2001;21(6):717–730.

    Article  CAS  Google Scholar 

  237. Conley R, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 2001;158:765–774.

    Article  CAS  Google Scholar 

  238. Allison DB, Mentore JL, Moonseong H, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686–1696.

    CAS  Google Scholar 

  239. Stimmel G, Dopheide JA, Stahl SM. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997;17(1):10–21.

    CAS  Google Scholar 

  240. Leinonen E, Skarstein J, Behnke K, et al. Efficacy and tolerability or mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Int Clin Psychopharmacol 1999;14(6):329–337.

    Article  CAS  Google Scholar 

  241. Remeron® (mirtazapine) prescribing information, July 2007. Organon, USA. Roseland, NJ. Available at: http://www.fda.gov/cder/foi/label/2007/020415s019,021208s010lbl.pdf. 2008.

  242. Holt RA, Maunder EMW. Is lithium-induced weight gain prevented by providing healthy eating advice at the commencement of lithium therapy? J Hum Nutr Diet 1996;9(2):127–133.

    Article  Google Scholar 

  243. Chen Y, Silverstone T. Lithium and weight gain. Int Clin Psychopharmacol 1990;5(3):217–225.

    Article  CAS  Google Scholar 

  244. Monane M, Gurwitz J, Bohn R, et al. The impact of thiazide diuretics on the initiation of lipid-reducing agents in older people: a population-based analysis. J Am Geriatr Soc 1997;45(1):71–75.

    CAS  Google Scholar 

  245. Guay DRP. Hyponatremia associated with selective serotonin reuptake inhibitors. Consult Pharm 2000;15(2):160–177.

    Google Scholar 

  246. Booker JA. Severe symptomatic hyponatremia in elderly outpatients: the role of thiazide therapy and stress. J Am Geriatr Soc 1984;32(2):108–113.

    CAS  Google Scholar 

  247. Kugler JP, Hustead T. Hyponatremia and hypernatremia in the elderly. Am Fam Physician 2000;61:3623–3630.

    CAS  Google Scholar 

  248. Christe C, Vogt N. SSRI-induced SIADH in older people. J Am Geriatr Soc 1999;47(5):630–631.

    CAS  Google Scholar 

  249. Spigset O, Hedenmalm K. Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug events. Pharmacotherapy 1997;17(2):348–352.

    CAS  Google Scholar 

  250. Odeh M, Beny A, Oliven A. Severe hyponatremia during citalopram therapy. Am J Med Sci 2001;321:159–160.

    Article  CAS  Google Scholar 

  251. Miyaoka R, Seno H, Itoga M, et al. Contribution of sodium valproate to the syndrome of inappropriate antidiuretic hormone. [abstract] Int Clin Psychopharmacol 2001;16:59–61.

    Article  CAS  Google Scholar 

  252. Shaikh ZH, Taylor HC, Maroo PV, et al. Syndrome of inappropriate antidiuretic hormone secretion associated with lisinopril. Ann Pharmacother 2000;334:176–179.

    Article  Google Scholar 

  253. van Assen S, Muddle AH. Severe hyponatremia in an amiloride/hydrochlorothiazide-treated patient. [abstract] Neth J Med 1999;54:108–113.

    Article  Google Scholar 

  254. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000;342(21):1581–1589.

    Article  CAS  Google Scholar 

  255. Tolstoi LG. Drug-induced hyperkalemia. Hosp Pharm 1996;31(3):221–228.

    Google Scholar 

  256. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors: how much should we worry? Arch Intern Med 1998;158(1):26–32.

    Article  CAS  Google Scholar 

  257. Chew M, Bult J, Schiff G. Drug-induced hyperkalemia. Hosp Pharm 2001;36(6):684,687.

    Google Scholar 

  258. Wehring H, Alexander B, Perry PJ. Diabetes mellitus associated with clozapine therapy. Pharmacotherapy 2000;20(7):844–847.

    Article  CAS  Google Scholar 

  259. Sobel M, Jaggers ED, Franz MA. New-onset diabetes mellitus associated with the initiation of quetiapine treatment. J Clin Psychiatry 1999;60:556–557.

    Article  CAS  Google Scholar 

  260. Lindenmayer JP, Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus. Am J Psychiatry 1999;156(9):1471.

    CAS  Google Scholar 

  261. Ober S, Hudak R, Rusterholtz A. Hyperglycemia and olanzapine [letter]. Am J Psychiatry 1999;156(6):970.

    CAS  Google Scholar 

  262. Gatta B, Rigalleau V, Gin H. Diabetic ketoacidosis with olanzapine treatment. Diabetes Care 1999;22(6):1002–1003.

    Article  CAS  Google Scholar 

  263. Hedenmalm K, Hagg S, Stahl M, et al. Glucose intolerance with atypical antipsychotics. Drug Safety 2002;25(15):1107–1116.

    Article  CAS  Google Scholar 

  264. U.S. Food and Drug Administration. Guidance for industry: content and format for geriatric labeling, October 2001. Available from: http://www.fda.gov/cber/gdlns/gerlab.pdf. Accessed May 2008.

  265. U.S. Food and Drug Administration. Guideline for industry: studies in support of special populations: Geriatrics August 1994. http://www.fda.gov/cder/guidance/iche7.pdf. Accessed 2008.

  266. U.S. Food and Drug Administration. Investigational New Drug Applications and New Drug Applications: Final Rule. 21 CFR parts 312 and 314. # 95 N-0010. http://www.Fda.gov/oashi/patrep/demo.html.

  267. U.S. Food and Drug Administration. Guidance for industry: drug interaction studies – study design, data analysis, and implications for dosing and labeling. Food and Drug Administration: Rockville, MD, September 2006. Available at http://www.fda.gov/cder/guidance/6695dft.pdf. Accessed May 2008.

  268. Budden F. Adverse drug reactions in long term care facility residents. J Am Geriatr Soc 1985;33:449–450.

    CAS  Google Scholar 

  269. LeCouteur DG, McLean AJ. The aging liver: drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 1998;34:359–373.

    Article  CAS  Google Scholar 

  270. Owens NJ, Silliman RA, Fretwell MD. The relationship between comprehensive functional assessment and optimal pharmacotherapy in the older patient. DICP 1989;23:847–853.

    CAS  Google Scholar 

  271. Health and Public Policy Committee, American College of Physicians. Comprehensive functional assessment for elderly patients. Ann Intern Med 1988;109:70–72.

    Google Scholar 

  272. Miller KE, Zylstra RG, Standridge JB. The geriatric patient: a systematic approach to maintaining health. Am Fam Physician 2000;61(4):1089–1104.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Pennsylvania, Philadelphia, PA, USA

    Bruce P. Kinosian MD (Associate Professor of Medicine)

  2. Wyeth Pharmaceuticals, Philadelphia, PA, USA

    Tanya C. Knight-Klimas PHARMD (Clinical Specialist)

Authors
  1. Bruce P. Kinosian MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tanya C. Knight-Klimas PHARMD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Nursing, University of Pennsylvania, Guardian Dr. 420, Philadelphia, 19104, U.S.A.

    Joseph I. Boullata

  2. Dept. Surgery, Temple University Hospital, N. Broad St. 3401, Philadelphia, 19140, U.S.A.

    Vincent T. Armenti

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Kinosian, B.P., Knight-Klimas, T.C. (2009). Drug–Nutrient Interactions in the Elderly. In: Boullata, J., Armenti, V. (eds) Handbook of Drug-Nutrient Interactions. Nutrition and Health. Humana Press. https://doi.org/10.1007/978-1-60327-362-6_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-362-6_22

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60327-363-3

  • Online ISBN: 978-1-60327-362-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation